Bone marrow function during quadruple immunosuppressive therapy after renal transplantation

Area of Science:

• Nephrology
• Immunology
• Hematology

Background:

• Renal transplantation requires immunosuppression.
• Quadruple immunotherapy is a common regimen.
• Bone marrow toxicity is a potential complication.

Purpose of the Study:

• Evaluate bone marrow function in renal transplant patients on quadruple immunotherapy.
• Identify risk factors for thrombocytopenia and leucopenia.
• Suggest strategies to mitigate these side effects.

Main Methods:

• Retrospective analysis of 50 renal transplant recipients.
• Monitoring of bone marrow parameters, including platelet and white blood cell counts.
• Correlation of adverse events with specific immunosuppressive agents and patient characteristics.

Main Results:

• Thrombocytopenia occurred in 30% of patients, often within 3 days of surgery.
• Anti-lymphocyte globulin (ALG) treatment and low admission platelet count were significant risk factors.
• Female sex, low weight, and long dialysis duration also contributed to thrombocytopenia risk.

Conclusions:

• Thrombocytopenia incidence can be reduced by adjusting azathioprine dosage in high-risk patients.
• Limiting ALG treatment duration and carefully managing azathioprine are key strategies.
• Cyclosporine showed no significant toxic effect on bone marrow.